Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.

#weightloss #weightlossmedications #obesity #Lilly #EliLilly #hearthealthdata #Mounjaro #tirzepatide #GLP1agonists #cardiovascularoutcomes #SURPASSCVOTtrial #dualGLP1GIPagonist #GLP1drug #MACE #heartattackprevention #strokeprevention #MACEendpoints #CVD #cardiometabolichealth
zurl.co/9w8Sk